Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
Clinical trial NCT02663622 · COMPLETED
Trial details
- NCT number
- NCT02663622
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-19
- Primary completion
- 2020-06-08
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.